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Abstract 
Background: The co-existence of autoimmunity and primary antibody deficiency in some individiuals is 
intriguing. The transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) 
gene (TNFRSF13B) has been implicated in both autoimmunity and primary antibody deficiency to varying 
extents in mice and humans. However, the phenotype described in mice with TNFRSF13B polymorphisms 
has not been entirely consistent with patients with similar orthologous polymorphisms. Objective: To 
further understand the relationship between TNFRSF13B variants and PAD and autoimmunity, we set out 
to determine the association of the two most common TNFRSF13B polymorphisms with autoimmunity 
and immunodeficiency, in patients with primary antibody deficiency and SLE. Method: We genotyped the 
C104R and A181E polymorphisms of TNFRSF13B in193 individuals and 144 controls from the Australian 
and New Zealand Antibody Deficiency Allele (ANZADA) Study, 107 patients from the Australian Point 
Mutation in Systemic Lupus Erythematosus (APOSLE) study, 169 patients with SLE from a European 
population, and 263 European controls. We were also able to determine TNFRSF13B genotypes for family 
members for nine of twelve pedigrees with primary antibody deficiency identified with TNFRSF13B 
variants. Results: The total number of TNFRSF13B variants in the primary antibody deficiency cohort was 
significantly higher than in the control group (p=0.0089; OR 9.481 [95% CI 1.218−73.81]). Similar results 
were obtained when patients with systemic lupus erythematosus were analysed. TNFRSF13B variants 
were strongly associated with SLE (p=0.0161, OR 3.316 [95% CI 1.245-8.836]). Familial analysis revealed 
incomplete penetrance of the TNFRSF13B variants. Conclusion: Taken together, the two most common 
TNFRSF13B variants are associated with primary antibody deficiency and systemic lupus erythematosus. 
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Abstract
Background: The co-existence of autoimmunity and primary antibody deficiency in some individiuals is
intriguing. The transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) gene
(TNFRSF13B) has been implicated in both autoimmunity and primary antibody deficiency to varying extents in mice
and humans. However, the phenotype described in mice with TNFRSF13B polymorphisms has not been entirely
consistent with patients with similar orthologous polymorphisms.
Objective: To further understand the relationship between TNFRSF13B variants and PAD and autoimmunity, we
set out to determine the association of the two most common TNFRSF13B polymorphisms with autoimmunity and
immunodeficiency, in patients with primary antibody deficiency and SLE.
Method: We genotyped the C104R and A181E polymorphisms of TNFRSF13B in193 individuals and 144
controls from the Australian and New Zealand Antibody Deficiency Allele (ANZADA) Study, 107 patients from the
Australian Point Mutation in Systemic Lupus Erythematosus (APOSLE) study, 169 patients with SLE from a
European population, and 263 European controls. We were also able to determine TNFRSF13B genotypes for
family members for nine of twelve pedigrees with primary antibody deficiency identified with TNFRSF13B variants.
Results: The total number of TNFRSF13B variants in the primary antibody deficiency cohort was significantly
higher than in the control group (p=0.0089; OR 9.481 [95% CI 1.218−73.81]). Similar results were obtained when
patients with systemic lupus erythematosus were analysed. TNFRSF13B variants were strongly associated with SLE
(p=0.0161, OR 3.316 [95% CI 1.245-8.836]). Familial analysis revealed incomplete penetrance of the TNFRSF13B
variants.
Conclusion: Taken together, the two most common TNFRSF13B variants are associated with primary antibody
deficiency and systemic lupus erythematosus.
Clinical & Cellular Immunology Chew et al., J Clin Cell Immunol 2014, 5:4http://dx.doi.org/10.4172/2155-9899.1000233
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Introduction
Non-congenital primary antibody deficiency (NCPAD) includes
common variable immunodeficiency (CVID), selective IgA deficiency
(sIgAD), immunoglobulin G subclass deficiency (IgGSD) and specific
antibody deficiency (SAD). Shared genetic aetiology amongst these
conditions is suggested by observations that different forms of
NCPAD cluster within the same kindred, and that in some individuals,
less severe forms of immunoglobulin deficiency can progress to
complete antibody deficiency [1-3]. In many patients, there is evidence
of additional immunological defects in the form of autoimmune
disease ranging from autoimmune haematological disease, which is the
most common, occurring in approximately 11% of patients, to solid
organ-specific autoimmunity and systemic conditions, which also
occur in up to 11% of patients [4-7]. These systemic autoimmune
diseases include rheumatoid arthritis, sicca syndrome, vasculitis and in
particular for this paper, systemic lupus erythematosus (SLE).
A number of studies have identified an increased incidence of
antibody defects among patients with autoimmune disease. In a
retrospective study of 33 children with an array of autoimmune
diseases including systemic diseases such as systemic lupus
erythematosus, autoimmune cytopenias and organ specific
autoimmune conditions such as Hashimoto’s thyroiditis, autoimmune
hepatitis and alopecia areata, 12% of children with autoimmune
diseases have some form of NCPAD [8]. Another study established
that 4.6% of SLE cases and 4.3% of juvenile idiopathic arthritis cases
have sIgAD, which is 10-20 times greater than the prevalence in the
general population [9]. There have also been reports of SLE preceeding
the onset of hypogammaglobulinemia [10,11]. Furthermore, in a series
of 326 patients with CVID, clinical evidence of autoimmunity
appeared prior to the onset of immunodeficiency in 54% of patients
with autoimmune haematological manifestations [7]. Similarly, Michel
and co-workers described a cohort where the initial manifestation in
62% of the 21 patients with CVID and ITP was thrombocytopenia
[12].
One explanation for this intriguing association is that immune
dysregulation contributes to both immunodeficiency and
autoimmunity. We will consider the underlying mechanisms including
some of own data and a review of published literature to set these
findings in context. In particular, we describe genetic variants that
appear to be shared between SLE and CVID.
Polymorphisms in the transmembrane activator and calcium
modulator and cyclophilin ligand interactor (TACI) gene
(TNFRSF13B) have been identified in patients with primary antibody
deficiencies [13,14]. Disease associated variants include C104R,
A181E, R202H, S114X and S194X [13,14]. Polymorphisms of
TNFRSF13B also occur in people with no evidence of immune
deficiency, including healthy relatives of CVID patients [13,15,16].
The most robust associations appear to be between polymorphisms
encoding C104R and A181E and CVID [17]. Together, these variants
have been identified in up to 10% of individuals with CVID, compared
with up to 2% of immune competent controls [13,14,18,19]. While one
study found an increased prevalence of TNFRSF13B variant in patients
with sIgAD [14], this has not been replicated in other studies [15,20].
In   summary,   C104R   and  A181E   polymorphisms   appear   to  act 
dominantly to increase the risk of antibody deficiency.
The mechanism that accounts for this association remains unclear.
Total serum immunoglobulin levels were not impaired in TACI-/- mice
[21,22]. Indeed, these mice developed features of autoimmunity
(diffuse membranoproliferative glomerulonephritis, positive
antinuclear antibodies and double stranded DNA antibodies
consistent with systemic lupus erythematosus (SLE)),
lymphoproliferation and splenomegaly, and 15% went on to develop
lymphoma [22,23]. Autoimmunity, lymphoproliferation and
splenomegaly were not seen in all individual mice with TNFRSF13B
polymorphisms.
The amino acid sequences surrounding both the C104R and A181E
variants are highly conserved between humans and mice. The C104R
variant in the extracellular domain disrupts the cysteine-rich region
that is vital for ligand binding [24,25]. More recently, Lee and
colleagues produced evidence of TACI haploinsufficiency in mice
heterozygous for the orthologous variant to human C104R (C76R) [26].
Although the mice had evidence of defective T cell-independent
responses to polysaccharides and decreased serum IgM, serum IgG
and IgA levels were normal [26]. There was no evidence of B cell
lymphoproliferation or splenomegaly. Mice with the A144E variant,
the murine ortholog of human A181E variant, exhibited reduced
serum IgA and IgM as well as impaired responses to T cell-
independent antigens [27], but did not develop B cell
lymphoproliferation or anti-DNA antibodies.
Here, we report the association between between the A181E and
C104R polymporphisms of TNFRSF13B in patients with primary
antibody deficiency and SLE.
Method
Subjects
We genotyped 193 individuals and 144 controls from the Australian
and New Zealand Antibody Deficiency Allele (ANZADA) Study, 107
patients from the Australian Point Mutation in Systemic Lupus
Erythematosus (APOSLE) study, 169 patients with SLE from a
European population, and 263 European controls. The controls
consisted of individuals without a personal or family history of
immunodeficiency or autoimmunity, drawn from the same
population. Ethics approval was obtained from each participating
institution.
Genotyping
Genomic DNA was extracted from saliva collected from subjects
using the Oragene DNA collection kit (DNA Genotek, Ontario,
Canada), based on the protocol provided by the manufacturer. Allele-
specific forward primers and the common reverse primer for both
C104R (GAAGGTCGGAGTCAACGGATTCCCTAAGCAATGTGCA
TACTTCC, GAAGGTGACCAAGTTCATGCTACCCTAAGCAATGT
GCATACTTCT   and   TGGGCTCCTGAGCTTGTT)   and   A181E
(GAAGGTGACCAAGTTCATGCTTCTGCTGCTTCCTGGTGGA, A
AGGTCGGAGTCAACGGATTTGCTGCTTCCTGGTGGC and GAC
TTTGACGGGGCCTT) single nucleotide polymorphisms (SNP) were
designed using Amplifluor® Assay Architect Software
(www.apps.serologicals.com/AAA, Millipore, MA, USA).
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A cocktail consisting of water, deoxynucleotide triphosphates,
platinum TAQ polymerase (Invitrogen, Carlsbad,Calif), 20Amplifluor
SNP FAM primer, 20Amplifluor SNP JOE primer, SNP-specific
primers, and 10reaction mix S plus is added to individual DNA
samples and a PCR program was run on a thermocycler. Subsequent to
the completion of the PCR procedure, samples were cooled to room
temperature and analyzed on the FLUOstar OPTIMA microplate
reader (BMG Labtech, Offenburg, Germany). Results obtained from
the microplate reader were transferred to a Microsoft Excel macro
provided by Millipore and analysed.
Sequencing was also used to confirm subsets from each Amplifluor
genotype. Thus, DNA from representative samples from each
Amplifluor® run, encoding the wild-type and heterozygous and
homozygous variants, was sequenced after the region was amplified by
PCR using the conventionally designed primers  (C104R - 5'-CTTTGT
GGTCAAACCCAGAG-3' and 5'-CTGGGCTTCATGCATTGTGG-3’;
A181E - 5'-TTGAGCCTAATGACGGGAAG-3' and 5'-CTGCCAGGA
TGTCTTAACCTG-3')  to  confirm  the  validity  of  the  Amplifluor® 
results.
DNA from patients with NCPAD that were found to have either the
C104R or A181E variant was amplified by PCR and sequenced by
conventional sequencing to exclude the possibility of biallelic
TNFRSF13B   variants,   using   the   following   primers   (Exon   1 - 5’-
GGGTGTGGCTGATTTACAT-3’ and 5’-CTTTGCACCTGCTGGAC-3’;
Exon 2 - 5’-GCCCCAGGCCCCTAGCAAGTG-3’ and 5’TCTCCTCCT
GCCACCCTTTCCTCA-3’; Exon 3 - 5'-CTTTGTGGTCAAACCCAGA
G-3'and 5'-CTGGGCTTCATGCATTGTGG-3’;   Exon 4 - 5'-TTGAGC
CTAATGACGGGAAG-3' and 5'-CTGCCAGGATGTCTTAACCTG-3';
Exon 5 - 5’-GTGATTGCCCTTAGCTCCTG-3' and 5'-TCTCCATCTC
TCCCTCCTC-3').
Statistics
Genotypic and allelic frequencies were compared using the Fisher
exact test. These tests, together with the OR, relative risk and 95% CI
were performed with GraphPad Prism 5.0 software (Graph-Pad
Software, La Jolla, Calif). Comparisons were considered significant at
p< 0.05.
Results
Frequency of C104R and A181E in NCPAD
We assessed the prevalence of the TNFRSF13B C104R and A181E
encoding polymorphisms in 193 patients with NCPAD from the
ANZADA cohort, including 171 with a diagnosis of CVID. The
remainder had a diagnosis of IgG subclass deficiency (IgGSD, n=11),
specific antibody deficiency (SAD, n=6) or immunoglobulin A
deficiency (IgAD, n=5).
In the NCPAD cohort, 12 individuals (6.22%) possessed either
A181E (n=6) or C104R (n=6) TNFRSF13B polymorphisms. No
homozygous variants were detected in the cohort. The prevalence of
C104R in the NCPAD cohort was not significantly different to the
controls, p=0.2458, but the prevalence of A181E was significantly
higher, p=0.0389 (Table 1). The total number of TNFRSF13B variants
in the NCPAD cohort was also significantly higher than in the control
group (p=0.0089; OR 9.481 [95% CI 1.218−73.81]) (Table 2).
Similar results were obtained when we analysed according to CVID
rather than all NCPAD. Here, C104R was not significantly more
common in the patient group (4/171 [2.33%]) than the controls (1/144
[0.69%]), p=0.3803 (Table 1). The result was similar for A181E
(p=0.0651), with five CVID patients (2.92%) possessing the variant
compared to none of the controls (Table 1). However, the association
between CVID and the two TNFRSF13B polymorphisms combined
was significant (p=0.0240; OR 7.944 [95% CI 0.9938−63.51]) (Table 2).
The other two subjects with C104R variants in this cohort had a
diagnosis of IgGSD while the other patient with A181E had a diagnosis
of SAD. None of the patients had biallelic variants in TNFRSF13B.
Frequency of C104R and A181E in autoimmunity
We next tested the association between C104R and A181E
polymorphisms and autoimmunity in the NCPAD cohort. In the
Australian NCPAD cohort, 43/193 (22%) individuals had one or more
manifestations of autoimmunity, including autoimmune
haematological cytopenia, arthritis, autoimmune thyroid disease,
Sjogren’s syndrome, vitiligo, psoriasis, autoimmune Addison’s disease
and alopecia areata [5]. Of the six individuals with the C104R variant,
only one patient (with a diagnosis of CVID) had features of
autoimmunity (pernicious anaemia and Sjogren’s syndrome) while
three out of six individuals who were heterozygous for A181E had
features of autoimmunity. These three individuals with CVID had
histories of autoimmune thyroiditis (one individual) and autoimmune
cytopenias (two individuals). No association was found between
C104R or A181E in NCPAD patients with autoimmunity (p=0.871
and p=0.246 respectively). There was also no association when both
variants were combined (p=0.5538).
The frequencies of C104R and A181E were next determined in
patients with SLE (Australian Point Mutation in SLE, APOSLE
cohort). The C104R variant was more prevalent than the A181E
variant in the Australian SLE cohort. 4/107 (3.74%) SLE patients
possessed the C104R polymorphism while none had the A181E
polymorphism. Although the C104R polymorphism was more
prevalent than in the Australian control cohort (3.74% vs 0.69%), this
difference did not reach statistical significance (p=0.1668).
These analyses were repeated in a second SLE cohort. In the
European SLE cohort, 6/169 (3.55%) individuals possessed a C104R
polymorphism while only 3/167 (1.80%) individuals possessed the
A181E variant. Two samples from the European cohort and one
control from the European control cohort did not amplify with the
A181E Amplifluor® assay or by direct PCR and these samples were
excluded from our analysis. The C104R polymorphism was 3.12 times
more common in the European SLE cohort than the European control
cohort (3.55% vs. 1.14%) while A181E was 2.36 times more common
(1.80% vs. 0.76%) in the European SLE cohort compared to the
European control cohort. In this European SLE cohort, the C104R
mutation was 1.98 times more common than the A181E
polymorphism (Table 3).
When the results from Australian and European SLE cohorts were
combined, C104R was significantly associated with SLE (p=0.0249, OR
3.797, [95% CI 1.178-12.24]) compared to combined Australian and
European control cohorts (Table 4), while A181E was not (p=0.3965)
(Table 5). Similarly the C allele in C104R was strongly associated with
SLE (p=0.0256, OR 3.745 [95% CI 1.168-12.01]). Furthermore, when
both heterozygous variants were combined in the analysis, they were
associated with SLE (p=0.0161, OR 3.316 [95% CI 1.245-8.836]) (Table
6).
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C104R Controls NCPAD Controls CVID
Genotype TT 143 (99.31) 187 (96.89) 143 (99.31) 167 (97.67)
CT 1 (0.69) 6 (3.11) 1 (0.69) 4 (2.33)
CC 0 0 0 (0.0) 0 (0.0)
Genotypic p
OR (95% CI)
2 x 2 p=0.2458
4.59 (0.55-38.56)
p=0.3803
C alleles TT 287 380 287 338
CT + CC 1 6 1 4
Allelic p
OR (95% CI)




CC 144 (100) 187 (96.89) 144 (100) 166 (97.08)
CA 0 (0) 6 (3.11) 0 (0) 5 (2.92)
AA 0 0 0 (0.0) 0 0)
2 x 2 p=0.0398
10.02 (0.56-179.4)
p=0.0651
A alleles CC 288 380 288 380
CA + AA 0 6 0 5
2 x 2 p=0.0406
9.857 (0.55-175.80)
p=0.0747
Data in parentheses show percentage prevalence or 95% CI
Table 1: C104R and A181E genotypes in NCPAD, CVID and controls.
Controls NCPAD Controls CVID
Wildtype 143 (99.31) 181 (93.78) 143 (99.31) 162 (94.74)
Heterozygotes 1 (0.69) 12 (6.22) 1 (0.69) 9 (5.26)
Genotypic p p=0.0089 p=0.0240
OR (95% CI) 9.481 (1.218-73.81) 7.944 (0.9938-63.51)
Data in parentheses show percentage prevalence or 95% CI
Table 2: TNFRSF13B variants in NCPAD, CVID and controls.
European SLE Controls P value
C104R 6/169 (3.55%) 3/264 (1.14%) 0.1632
A181E 3/167 (1.80%) 2/263 (0.76%) 0.3810
Data in parentheses show percentage prevalence.
Table 3: C014R and A181E genotypes in a European population.
-
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Controls SLE
Genotype TT 404 (99.02) 266 (96.38)
CT 4 (0.98) 10 (3.62)
CC 0 (0.0) 0 (0.0)
Genotypic p 2 x 2 p=0.0249
Odds ratio 3.797 (1.178-12.24)
C allele carriers TT 812 542
CT + CC 4 10
Allelic p 2 x 2 p=0.0256
Odds ratio 3.745 (1.168-12.01)
Data in parentheses show percentage prevalence or 95% CI.
Table 4: C104R genotypes in the combined Australian and European SLE and control cohorts.
Controls SLE
Genotype CC 405 (99.51) 271 (98.91)
CA 2 (0.49) 3 (1.09)
AA 0 (0.0) 0 (0.0)
Genotypic p 2 x 2 p=0.3965
A allele carriers CC 812 545
CA + AA 2 3
Allelic p 2 x 2 p=0.3971
Data in parentheses show percentage prevalence or 95% CI.
Table 5: A181E genotypes inthe combined Australian and European SLE and control cohorts.
Controls CVID
Wild-type 401 (98.53) 262 (95.27)
Heterozygotes 6 (1.47) 13 (4.73)
Genotypic p p=0.0161
OR (95% CI) 3.316 (1.245-8.836)
Data in parentheses show percentage prevalence or 95% CI.
Table 6: C104R and A181E inthe combined Australian and European SLE and control cohorts.
Familial segregation
We were able to determine TNFRSF13B genotypes for family
members for nine of twelve pedigrees identified with TNFRSF13B
variants. These are shown together with nine other pedigrees within
the cohort (Figure 1). While 12/18 pedigrees contain at least one
family member with autoimmunity, overall the prevalence in those
with TNFRSF13B single nucleotide variants is too low to assess for
evidence of transmission disequilibrium. In 8/18 pedigrees, at least one
relative had clinical evidence of autoimmunity. In some pedigrees,
multiple relatives of probands with antibody deficiency had evidence
of autoimmunity alone.
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Figure 1: Pedigrees of patients with antibody deficiency with coexisting a) C104R polymorphism of TNFRSF13B; b) A181E polymorphism of
TNFRSF13B; c) wild-type TNFRSF13B.
Discussion
With regard to antibody deficiency, our results are similar to those
reported for other cohorts. In a large cohort of 564 patients with
hypogammaglobulinemia (predominantly CVID, 94.5%) and 675
controls, Salzer and colleagues [16] found the two most common
variants to be C104R (4.6%) and A181E (2.3%). Only one patient from
each group had homozygous variants. In the control cohort, 1% had
the A181E polymorphism while 0.9% possessed the C104R
polymorphism. We report a similar prevalence of these genotypes in
the Australian (ANZADA) cohort, in both patients and controls,
yielding a similar association with disease (A181E, p=0.0398, OR,
10.02; 95% CI, 0.56-179.4; C104R, p=0.2458, OR, 4.59; 95% CI,
0.55-38.56). When both polymorphisms were analysed together, the
association between NCPAD and TNFRSF13B variants became
significant (p=0.0089; OR, 9.481; 95% CI, 1.22-73.81). In isolation, the
results from this study would not achieve a high level of statistical
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certainty but the association and magnitude of effect is similar to that
reported elsewhere [16]. Taken together, we conclude that our
NCPAD population is similar with regard to these TNFRSF13B single
nucleotide variants.
Salzer and colleagues also found evidence to suggest that
autoimmune manifestations in NCPAD were more common in cases
with TACI deficiency, particularly with the heterozygous C104R
variant [16]. This is in contrast to the findings in the Australian
cohort, where there was no association between C104R or A181E
alone or in combination in individuals with both antibody deficiency
and autoimmunity.
By contrast, we found an association between TNFRSF13B and
autoimmunity in the absence of antibody deficiency. The C104R
polymorphism was more common in SLE (p=0.0249; OR, 3.797, 95%
CI 1.18- 12.24), but A181E was not (p=0.3965). When both these
variants were combined, the association of TACI with SLE reached
statistical significance (p=0.0161; OR, 3.316, 95% CI 1.17 - 12.01]).
This is at odds with another study in which 190 SLE subjects were
analysed and no association was found between C104R or A181E and
SLE [28].
A review of the literature regarding murine models of TNFRSF13B
did not clarify these conflicting findings seen in human studies.
Features of SLE are present in TACI knockout mice [21] but not mice
with the C76R or A144R polymorphisms (murine equivalents of
C104R and A181E respectively) [26,27]. Both TACI knockout mice
[21] and mice with the C76R polymorphism [26] demonstrated
impaired T cell-independent responses, but total serum IgG was not
reduced in either model. Mice with the A144E variant did not have
evidence of autoimmunity but had evidence of impaired antibody
responses, with reduced total serum IgA and IgM levels, and defective
responses to T cell-independent antigens [27].
The high prevalence of autoimmunity in the relatives of patients
with NCPAD irrespective of whether they are immunodeficient or
whether they possess TNFRSF13B variants, suggest that the risk of
autoimmunity exists in families with NCPAD (Figure 1). These
preliminary findings suggest that independent genetic modifiers might
act to promote either autoimmunity or immune deficiency.
Other PAD have been described with SLE. A number of series
report the association between selective IgA deficiency (IgAD) and
SLE [29-33]. There is a shared association between the HLA-B8, DR3,
DQ2 haplotype of IgAD and autoimmunity. Polymorphisms in non-
MHC regions, interferon induced helicase 1 (IFH-1) and the C-type
lectin family domain have been detected in recent genome wide
association study [34]. A small number of case reports associating SLE
and NCPAD with a toll-like receptor signalling defect [35], mannose
binding lectin gene polymorphisms [36] and thymoma [37] have been
reported. The mechanism underpinning these associations is unclear
but has led to the suggestion that IgAD may itself be an autoimmune
disease [33].
In summary, the incomplete penetrance revealed by familial
analysis and the modest effect of TNFRSF13B polymorphisms on the
risk of antibody deficiency and autoimmunity suggest that other
interacting factors may play a role in determining whether an
individual with a TNFRSF13B variant develop antibody deficiency or
autoimmunity. The association between autoimmunity and
immunodeficiency reminds us to not disregard the possibility of
immunodeficiency in the setting of SLE.
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